Form 8-K

8-K — Prestige Consumer Healthcare Inc.

Accession: 0001295947-26-000013

Filed: 2026-05-13

Period: 2026-05-13

CIK: 0001295947

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — pbh-20260513.htm (Primary)

EX-99.1 (exhibit991fy26-q4earningsr.htm)

EX-99.2 (exhibit992pbh_fy26xq4.htm)

GRAPHIC (exhibit992pbh_fy26xq4001.jpg)

GRAPHIC (exhibit992pbh_fy26xq4002.jpg)

GRAPHIC (exhibit992pbh_fy26xq4003.jpg)

GRAPHIC (exhibit992pbh_fy26xq4004.jpg)

GRAPHIC (exhibit992pbh_fy26xq4005.jpg)

GRAPHIC (exhibit992pbh_fy26xq4006.jpg)

GRAPHIC (exhibit992pbh_fy26xq4007.jpg)

GRAPHIC (exhibit992pbh_fy26xq4008.jpg)

GRAPHIC (exhibit992pbh_fy26xq4009.jpg)

GRAPHIC (exhibit992pbh_fy26xq4010.jpg)

GRAPHIC (exhibit992pbh_fy26xq4011.jpg)

GRAPHIC (exhibit992pbh_fy26xq4012.jpg)

GRAPHIC (exhibit992pbh_fy26xq4013.jpg)

GRAPHIC (exhibit992pbh_fy26xq4014.jpg)

GRAPHIC (exhibit992pbh_fy26xq4015.jpg)

GRAPHIC (exhibit992pbh_fy26xq4016.jpg)

GRAPHIC (exhibit992pbh_fy26xq4017.jpg)

GRAPHIC (exhibit992pbh_fy26xq4018.jpg)

GRAPHIC (exhibit992pbh_fy26xq4019.jpg)

GRAPHIC (exhibit992pbh_fy26xq4020.jpg)

GRAPHIC (exhibit992pbh_fy26xq4021.jpg)

GRAPHIC (exhibit992pbh_fy26xq4022.jpg)

GRAPHIC (exhibit992pbh_fy26xq4023.jpg)

GRAPHIC (exhibit992pbh_fy26xq4024.jpg)

GRAPHIC (exhibit992pbh_fy26xq4025.jpg)

GRAPHIC (exhibit992pbh_fy26xq4026.jpg)

GRAPHIC (exhibit992pbh_fy26xq4027.jpg)

GRAPHIC (exhibit992pbh_fy26xq4028.jpg)

GRAPHIC (exhibit992pbh_fy26xq4029.jpg)

GRAPHIC (exhibit992pbh_fy26xq4030.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: pbh-20260513.htm · Sequence: 1

pbh-20260513

0001295947false00012959472026-05-132026-05-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 13, 2026

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-32433 20-1297589

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

660 White Plains Road, Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common stock, par value $0.01 per share PBH New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 1.01 Entry into a Material Definitive Agreement.

On May 10, 2026, PBH Australia Holding Company Pty Limited (“Purchaser”), an Australian company and a wholly owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), and Care Pharmaceuticals Pty Limited (“Care”), an Australian company and a wholly owned indirect subsidiary of the Company, entered into a definitive agreement (the “Sale and Purchase Deed”) with Tailor Investments Pty Limited and Standive Pty Limited, both Australian companies (the “Sellers”), Steven David Sher, Delon Badler and Clive Howard Sher. The Sale and Purchase Deed provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire all of the shares of LaCorium Health Australia Pty Limited, Stantail Trading Pty Limited, Stantail International Pty Limited, Brands Worldwide Holdings I.P. Pty Limited, and Laderma Holdings Pty Limited, each an Australian company, collectively a leader in Australian therapeutic skin care designed to treat individual skin ailments, from the Sellers for approximately $150 million in cash, subject to certain adjustments, including indebtedness, as provided in the Sale and Purchase Deed (the “Transaction”).

The Company expects the Transaction to close in the second quarter of fiscal 2027, subject to the satisfaction or waiver of customary conditions to closing.

The Sale and Purchase Deed contains customary representations, warranties, indemnities, and covenants of both Purchaser and the Sellers, as well as indemnification provisions that are subject to specified limitations. Purchaser has obtained warranty and indemnity insurance, which serves as Purchaser’s sole recourse for losses related to breaches of the Sellers’ representations, warranties and indemnities, other than in the case of fraud. Subject to certain exceptions and limitations, Purchaser and Care, on the one hand, and the Sellers and Steven David Sher, on the other hand, have agreed to indemnify each other for breaches of post-closing covenants, fraud and other specified matters contained in the Sale and Purchase Deed.

The Sale and Purchase Deed also contains certain customary termination rights for each of Purchaser and the Sellers. The Sale and Purchase Deed may be terminated by either Purchaser or the Sellers prior to October 1, 2026 if the other party is in breach of the Sale and Purchase Deed, such that it has not met its closing conditions and has not or is not able to cure such breach.

The foregoing description of the terms of the Sale and Purchase Deed does not purport to be complete and is qualified in its entirety by reference to the full text of the Sale and Purchase Deed. The Company expects to file a copy of the Sale and Purchase Deed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

The Sale and Purchase Deed contains various representations and warranties made by the parties solely for purposes of the Sale and Purchase Deed and as of specific dates set forth therein, which were the product of negotiations, and may be subject to important qualifications and limitations included in confidential disclosure letter of the Sale and Purchase Deed. Certain representations and warranties in the Sale and Purchase Deed were used for the purpose of allocating risk between the parties, rather than establishing matters of fact. Furthermore, the representations and warranties may be subject to standards of materiality applicable to the parties that may be different from those applicable to the Company’s stockholders. Additionally, information concerning the subject matter of such representations and warranties may change after the date of the Sale and Purchase Deed, which subsequent information may or may not be fully reflected in the Company’s public disclosures. Accordingly, such representations and warranties in the Sale and Purchase Deed may not constitute the actual state of facts about the Sellers, the Company, or Purchaser. Stockholders of the Company are not third-party beneficiaries under the Sale and Purchase Deed t and should not rely on the representations, warranties, and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Sellers (or any of its subsidiaries), the Company, or Purchaser or any of their respective subsidiaries or affiliates.

Item 2.02 Results of Operations and Financial Condition.

On May 13, 2026, the Company announced financial results for the fiscal quarter and year ended March 31, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2026 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On May 13, 2026, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and year ended March 31, 2026, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”) and incorporated here-in by reference.  The Company expects

to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2027.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit Description

99.1

Press Release dated May 13, 2026 announcing the Company's financial results for the fiscal quarter and year ended March 31, 2026 (furnished only).

99.2

Investor Relations Slideshow in use beginning May 13, 2026 (furnished only).

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:

May 13, 2026

PRESTIGE CONSUMER HEALTHCARE INC.

By: /s/ Christine Sacco

Name: Christine Sacco

Title: Chief Financial Officer & Chief Operating Officer

EX-99.1

EX-99.1

Filename: exhibit991fy26-q4earningsr.htm · Sequence: 2

Document

Exhibit 99.1

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

•Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026

•Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026

•Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin care

•Introducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 13, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.

“Our fiscal 2026 demonstrated the resilience of our business model in a challenging consumer backdrop.

Our diversified portfolio of leading brands with deep consumer heritage supports a durable financial profile and drives strong, growing free cash flow. In fiscal 2026, this resulted in $246.4 million of free cash flow driven by continued strength that included strong growth for Fleet®, Dramamine®, and Hydralyte® in our Gastrointestinal category, which helped partially offset the impacts of limited eye care production as well as fourth quarter shipping disruptions in the Middle East.”

Fourth Fiscal Quarter Ended March 31, 2026

Reported revenues in the fourth quarter of fiscal 2026 of $281.6 million decreased 5.0% from $296.5 million in the fourth quarter of fiscal 2025 and decreased 6.4% versus the prior fiscal fourth quarter excluding the impact of foreign currency. The revenue performance versus the prior year comparable period reflected lower Eye & Ear Care category sales, driven primarily by limited ability to supply demand for Clear Eyes® and the expected headwind associated with accelerated order timing in the fourth quarter of the prior year.

Reported net income for the fourth quarter of fiscal 2026 was $53.9 million versus the prior fiscal fourth quarter of $50.1 million. Diluted earnings per share of $1.13 for the fourth quarter of fiscal 2026 compared to $1.00 in the prior year comparable period. Non-GAAP adjusted net income for the fourth quarter of fiscal 2026 was $58.5 million compared to $65.9 million in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $1.23 for the fourth quarter of fiscal 2026 compared to $1.32 in the prior year comparable period.

Adjustments to net income in the fourth quarter of fiscal 2026 included certain costs associated with Pillar5, our recently acquired sterile eye care facility, including various costs associated with improving and optimizing the facility for increases in long-term capacity, as well as costs associated with acquisitions and associated tax adjustments as well as an adjustment to normalize the tax rate to account for discrete items.

Adjustments to net income in the fourth quarter of fiscal 2025 included non-cash tradename impairments and an associated tax adjustment as well as an adjustment to normalize the tax rate to account for discrete items.

Fiscal Year Ended March 31, 2026

Reported revenues for fiscal year 2026 totaled $1,088.7 million, a decrease of 4.3% versus revenues of $1,137.8 million in the prior fiscal year. Revenues decreased 4.5% versus the prior fiscal year excluding the impact of foreign currency. The revenue performance for the fiscal year reflected the limited ability to supply demand for Clear Eyes®.

Reported net income for fiscal 2026 of $190.3 million compared to $214.6 million in the prior year. Reported fiscal 2026 diluted earnings per share was $3.91, compared to $4.29 in the prior year. On a non-GAAP adjusted basis, fiscal 2026 adjusted net income of $213.3 million and adjusted diluted earnings per share of $4.38 compared to adjusted net income and adjusted diluted earnings per share of $226.3 million and $4.52 in the prior year, respectively.

Adjustments to net income in fiscal 2026 include certain costs associated with Pillar5, our recently acquired sterile eye care facility, including various costs associated with improving and optimizing the facility for long-term capacity. Additional adjustments to net income in fiscal 2026 include a supplier loan write-off, costs associated with acquisitions, and associated tax adjustments as well as an adjustment to normalize the tax rate to account for discrete items.

Adjustments to net income in fiscal 2025 included non-cash tradename impairments associated with non-strategic indefinite-lived and finite-lived intangible assets, and an associated tax adjustment as well as an adjustment to normalize the tax rate to account for discrete items.

Segment Review

North American OTC Healthcare: Segment revenues of $234.5 million for the fourth quarter of fiscal 2026 decreased compared to the prior year comparable quarter's segment revenues of $248.9 million. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven by limited ability to supply demand for Clear Eyes®.

For fiscal 2026, reported revenues for the North American OTC segment were $913.6 million, which compared to $960.0 million in the prior year. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven by limited ability to supply demand for Clear Eyes® and the expected headwind associated with accelerated order timing in Q4 of the prior year.

International OTC Healthcare: Fiscal fourth quarter 2026 segment revenues of $47.1 million compared to $47.6 million reported in the prior year comparable period. The lower revenue performance was driven by shipping disruptions in the Middle East and lower Eye & Ear Care category sales.

For fiscal 2026, reported revenues for the International OTC Healthcare segment were $175.1 million, a decrease over the prior year’s revenues of $177.8 million, driven by lower Eye & Ear Care category sales and fourth quarter shipping disruptions, which were partly offset by an increase in the Women’s Health and Cough & Cold categories.

Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for fiscal 2026 was $257.6 million, an increase compared to $251.5 million in the prior year. Non-GAAP free cash flow in fiscal 2026 of $246.4 million increased from $243.3 million in the prior year.

In fiscal 2026, the Company opportunistically repurchased 2.3 million shares at a total investment of approximately $156 million.

The Company's net debt position as of March 31, 2026 was approximately $0.9 billion, resulting in a covenant-defined leverage ratio of 2.6x.

LaCorium Acquisition

The Company today is also announcing a definitive agreement to acquire LaCorium Health (“LaCorium”), for approximately $150 million in cash. The transaction, subject to customary conditions, is expected to close in second quarter fiscal 2027.

LaCorium generated approximately $40 million in trailing twelve months revenue through February 28, 2026 and is expected to generate approximately $12 million in EBITDA including the benefits from anticipated synergies once the business is fully integrated. LaCorium is delivering strong growth, and the Company expects double-digit net sales growth in calendar 2026 driven by a combination of category growth, innovation, and continued geographic expansion.

Founded in Australia and introduced in 1998, LaCorium is a leader in Australian therapeutic skin care designed to treat individual skin ailments. Products are sold under the Dermal Therapy®, Flexitol®, and Crampeze® brands in need-state categories such as lip care (cold sores), skin care (eczema & acne), foot care (heel balm, antifungal), hair & scalp (eczema), and more. Approximately 75% of sales are in Australia, where the brand maintains a leading #1 market position in lip care and #3 in foot care. Globally, products are sold in approximately 20 countries across North America, Asia, and the Middle East under the Flexitol® and Crampeze® brand names.

Fiscal 2027 Outlook

Ron Lombardi, Chief Executive Officer, stated, “As we begin fiscal 2027, we anticipate our proven financial model and diversified portfolio of leading, trusted brands will result in sales growth approximate to our long-term expectations. Our organic sales growth outlook range reflects strong momentum for our diversified portfolio of leading strategic brands and also accounts for variability in eye care supply as we prioritize quality and increase output of Clear Eyes® as well as an expectation for a continued volatile consumer backdrop.”

He continued, “We anticipate adjusted diluted EPS of $4.42 to $4.51, following sales growth and adjusted free cash flow of $250 million or more. We expect to provide an updated outlook for the year after the completion of the acquisitions of Breathe Right® and LaCorium, which we anticipate closing in June and July, respectively. Regarding recent fluctuations in energy costs, just like other inflationary periods of the past, we plan to leverage our leading portfolio, diverse supply chain, and agile operating model to manage and mitigate these costs as they arise in our fiscal 2027 and moving forward,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Fiscal 2027 Outlook

Revenue

$1,100 million to $1,121 million

Organic Revenue Growth

+1.0% to +3.0%

Adjusted Diluted E.P.S.

$4.42 to $4.51

Free Cash Flow

$250 million or more

Medium-Term Outlook

“Based on the acquisitions expected to close early in fiscal 2027, our expanded portfolio of leading brands, and the continued recovery of our eye care capacity, we expect a meaningful strengthening of our overall business profile and positioning. Combined with our continued disciplined approach to capital allocation, this positions us to deliver growth over the next three years that exceeds our long-term targets. Over this period, we expect to generate an approximately 10% annual CAGR for revenue growth, an EPS growth CAGR of approximately 8%, and exceptional free cash flow approaching $900 million in aggregate. This level of cash generation is expected to enable a rapid return to historical leverage levels, further enhancing shareholder value. We have a long track record of delivering superior shareholder value and remain focused on executing our business model to achieve these objectives and drive continued value creation” Mr. Lombardi concluded.

Fiscal 2026 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its fourth quarter and fiscal 2026 results tomorrow morning, May 14, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com/. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as “durable,” “growing,” "outlook," “forecast,” "may," "will," "would," "expect," “positioned,” “anticipate,” “plan,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and free cash flow; the strength of the Company’s financial profile, improvements in eye care supply from the acquisition of Pillar5 and increased manufacturing capacity from capital investments; LaCorium’s net sales growth; the timing of the closing of acquisitions; the impact of volatile markets on consumer spending; the timing of the Company’s return to historical leverage; and the Company’s ability to manage and mitigate energy costs and enhance shareholder value. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs and trade actions, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at

www.prestigeconsumerhealthcare.com.

Prestige Consumer Healthcare Inc.

Consolidated Statement of Income and Comprehensive Income

(Unaudited)

Three Months Ended March 31, Year

Ended March 31,

(In thousands, except per share data) 2026   2025 2026   2025

Total Revenues 281,617    296,518  1,088,705    1,137,762

Cost of Sales

Cost of sales excluding depreciation 132,404  124,318  482,794  494,416

Cost of sales depreciation 2,914  2,190  10,333  8,883

Cost of sales 135,318  126,508  493,127  503,299

Gross profit 146,299    170,010  595,578    634,463

Operating Expenses

Advertising and marketing 35,089  37,004  148,782  155,723

General and administrative 30,280  27,050  116,447  108,209

Depreciation and amortization 5,438  5,062  20,940  21,290

Goodwill and tradename impairment —  12,466  —  12,466

Total operating expenses 70,807    81,582  286,169    297,688

Operating income 75,492    88,428  309,409    336,775

Other expense (income)

Interest expense, net 11,428  10,759  42,339  47,632

Other expense (income), net (708) 3,710  9,574  4,954

Total other expense, net 10,720    14,469  51,913    52,586

Income before income taxes 64,772  73,959  257,496  284,189

Provision for income taxes 10,844  23,831  67,195  69,584

Net income $ 53,928    $ 50,128  $ 190,301    $ 214,605

Earnings per share:

Basic $ 1.14  $ 1.01  $ 3.93  $ 4.32

Diluted $ 1.13  $ 1.00  $ 3.91  $ 4.29

Weighted average shares outstanding:

Basic 47,433  49,656  48,456  49,697

Diluted 47,686  50,064  48,720  50,080

Comprehensive income, net of tax:

Currency translation adjustments 1,962  2,586  9,387  (3,083)

Unrecognized net loss on pension plans (96) (81) (96) (81)

Total other comprehensive income (loss) 1,866  2,505  9,291  (3,164)

Comprehensive income $ 55,794  $ 52,633  $ 199,592  $ 211,441

Prestige Consumer Healthcare Inc.

Consolidated Balance Sheet

(Unaudited)

(In thousands) March 31,

2026 2025

Assets

Current assets

Cash and cash equivalents $ 63,868  $ 97,884

Accounts receivable, net of allowance of $18,187 and $16,314, respectively

191,920  194,293

Inventories 159,132  147,709

Prepaid expenses and other current assets 16,564  8,442

Total current assets 431,484    448,328

Property, plant and equipment, net 121,689  74,548

Operating lease right-of-use assets 27,780  28,238

Finance lease right-of-use assets, net 21,776  25,056

Goodwill 581,109  527,425

Intangible assets, net 2,299,605  2,295,350

Other long-term assets 10,870  3,273

Total Assets $ 3,494,313    $ 3,402,218

Liabilities and Stockholders' Equity

Current liabilities

Accounts payable $ 22,791  $ 18,925

Accrued interest payable 15,578  15,703

Operating lease liabilities, current portion 6,910  6,047

Finance lease liabilities, current portion 2,656  2,490

Other accrued liabilities 72,989  63,458

Total current liabilities 120,924    106,623

Long-term debt, net 993,953  992,357

Deferred income tax liabilities 447,417    419,594

Long-term operating lease liabilities, net of current portion 20,955  22,732

Long-term finance lease liabilities, net of current portion 17,968  20,624

Other long-term liabilities 5,580  5,391

Total Liabilities 1,606,797    1,567,321

Stockholders' Equity

Preferred stock - $0.01 par value

Authorized - 5,000 shares

Issued and outstanding - None —    —

Common stock - $0.01 par value

Authorized - 250,000 shares

Issued – 56,211 shares at March 31, 2026 and 56,010 shares at March 31, 2025

562  560

Additional paid-in capital 608,520  593,402

Treasury stock, at cost – 8,892 shares at March 31, 2026 and 6,501 at March 31, 2025

(439,301) (277,208)

Accumulated other comprehensive loss, net of tax (28,368) (37,659)

Retained earnings 1,746,103  1,555,802

Total Stockholders' Equity 1,887,516    1,834,897

Total Liabilities and Stockholders' Equity $ 3,494,313    $ 3,402,218

Prestige Consumer Healthcare Inc.

Consolidated Statement of Cash Flows

(Unaudited)

Year Ended March 31,

(In thousands) 2026   2025

Operating Activities

Net income $ 190,301  $ 214,605

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 31,273  30,173

Loss on sale or disposal of property and equipment 165  234

Deferred and other income taxes 22,697  14,409

Amortization of debt origination costs 1,797  1,754

Stock-based compensation costs 10,835  11,157

Non-cash operating lease cost 7,850  7,247

Write-off of supplier loan 10,332  —

Impairment loss —  12,466

Other —  1,411

Changes in operating assets and liabilities, net of effects from acquisition:

Accounts receivable (3,685) (16,327)

Inventories (1,597) (9,314)

Prepaid expenses and other current assets (6,968) 4,655

Accounts payable (151) (19,411)

Accrued liabilities 2,527  6,984

Operating lease liabilities (7,781) (7,630)

Other 32  (898)

Net cash provided by operating activities 257,627  251,515

Investing Activities

Purchases of property, plant and equipment (11,178) (8,224)

Acquisitions, net of cash acquired (123,736) (8,250)

Other (1,927) (978)

Net cash used in investing activities (136,841)   (17,452)

Financing Activities

Term Loan repayments —  (135,000)

Borrowings under revolving credit agreement 40,000  —

Repayments under revolving credit agreement (40,000) —

Net increase in line of credit 2,986  —

Payments of finance leases (2,482) (4,536)

Proceeds from exercise of stock options 4,285  14,802

Fair value of shares surrendered as payment of tax withholding (4,322) (5,832)

Repurchase of common stock (156,283) (51,509)

Other (246) —

Net cash used in financing activities (156,062)   (182,075)

Effects of exchange rate changes on cash and cash equivalents 1,260  (573)

(Decrease) increase in cash and cash equivalents (34,016)   51,415

Cash and cash equivalents - beginning of year 97,884  46,469

Cash and cash equivalents - end of year $ 63,868    $ 97,884

Interest paid $ 43,843  $ 47,804

Income taxes paid $ 45,944  $ 52,117

Prestige Consumer Healthcare Inc.

Consolidated Statement of Income

Business Segments

(Unaudited)

Three Months Ended March 31, 2026

(In thousands) North American OTC

Healthcare International OTC

Healthcare Consolidated

Total segment revenues* $ 234,545  $ 47,072  $ 281,617

Cost of sales 113,171  22,147  135,318

Gross profit 121,374  24,925  146,299

Advertising and marketing 27,174  7,915  35,089

Contribution margin $ 94,200  $ 17,010  111,210

Other operating expenses 35,718

Operating income 75,492

*Intersegment revenues of $1.5 million were eliminated from the North American OTC Healthcare segment.

Year Ended March 31, 2026

(In thousands) North American OTC

Healthcare International OTC

Healthcare Consolidated

Total segment revenues* $ 913,576  $ 175,129  $ 1,088,705

Cost of sales 412,699  80,428  493,127

Gross profit 500,877  94,701  595,578

Advertising and marketing 120,847  27,935  148,782

Contribution margin $ 380,030  $ 66,766  446,796

Other operating expenses   137,387

Operating income   $ 309,409

*Intersegment revenues of $3.8 million were eliminated from the North American OTC Healthcare segment.

Three Months Ended March 31, 2025

(In thousands) North American OTC

Healthcare International OTC

Healthcare Consolidated

Total segment revenues* $ 248,949  $ 47,569  $ 296,518

Cost of sales 107,463  19,045  126,508

Gross profit 141,486  28,524  170,010

Advertising and marketing 29,794  7,210  37,004

Contribution margin $ 111,692  $ 21,314  133,006

Other operating expenses** 44,578

Operating income $ 88,428

*Intersegment revenues of $1.4 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the three months ended March 31, 2025 includes a tradename impairment charge of $12.5 million.

Year Ended March 31, 2025

(In thousands) North American OTC

Healthcare International OTC

Healthcare Consolidated

Total segment revenues* $ 960,010  $ 177,752  $ 1,137,762

Cost of sales 428,871  74,428  503,299

Gross profit 531,139  103,324  634,463

Advertising and marketing 129,431  26,292  155,723

Contribution margin $ 401,708  $ 77,032  478,740

Other operating expenses** 141,965

Operating income $ 336,775

* Intersegment revenues of $3.9 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2025 includes a tradename impairment charge of $12.5 million.

About Non-GAAP Financial Measures

In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.

NGFMs Defined

We define our NGFMs presented herein as follows:

•Non-GAAP Organic Revenues: GAAP Total Revenues excluding the impact of foreign currency exchange rates in the periods presented.

•Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.

•Non-GAAP Adjusted Gross Margin: GAAP Gross Profit minus amortization of inventory fair value step-up, depreciation of idle manufacturing assets during remediation period and acquired facility remediation, period overhead and idle capacity costs.

•Non-GAAP Adjusted Gross Margin Percentage: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.

•Non-GAAP Adjusted General and Administrative Expense: GAAP General and Administrative expenses minus costs associated with acquisition and depreciation of idle assets recorded in General and Administrative expenses during remediation period.

•Non-GAAP Adjusted General and Administrative Expense Percentage: Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.

•Non-GAAP EBITDA: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.

•Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.

•Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA less amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisition in General and Administrative expenses, supplier loan write-off and tradename impairment.

•Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.

•Non-GAAP Adjusted Net Income: GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle manufacturing assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, supplier loan write-off, costs associated with acquisition in General and Administrative expenses, acquired facility depreciation, tradename impairment, tax impact of adjustments and normalized tax rate adjustment.

•Non-GAAP Adjusted Diluted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.

•Non-GAAP Free Cash Flow: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.

•Net Debt: Calculated as total principal amount of debt outstanding ($1,000,000 at March 31, 2026 and $1,000,000 at

March 31, 2025) less cash and cash equivalents ($63,868 at March 31, 2026 and $97,884 at March 31, 2025). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs to their most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:

Three Months Ended March 31, Year Ended

March 31,

2026 2025 2026 2025

(In thousands)

GAAP Total Revenues $ 281,617  $ 296,518  $ 1,088,705    $ 1,137,762

Revenue Change (5.0) % (4.3) %

Adjustment:

Impact of foreign currency exchange rates —  4,292  —  2,718

Total adjustment —  4,292  —  2,718

Non-GAAP Organic Revenues $281,617 $300,810 $1,088,705 $1,140,480

Non-GAAP Organic Revenue Change (6.4) % (4.5) %

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:

Three Months Ended March 31, Year Ended

March 31,

2026 2025 2026 2025

(In thousands)

GAAP Total Revenues $ 281,617  $ 296,518  $ 1,088,705    $ 1,137,762

GAAP Gross Profit 146,299    170,010  595,578    634,463

GAAP Gross Profit as a Percentage of GAAP Total Revenue 51.9  % 57.3  % 54.7  % 55.8  %

Adjustments:

Amortization of inventory fair value step‑up 700  —  700  —

Depreciation of idle manufacturing assets during remediation period (a)

475  —  475  —

Acquired facility remediation, period overhead and idle capacity costs (b)

8,402  —  8,402  —

Total adjustments 9,577  —  9,577  —

Non-GAAP Adjusted Gross Margin $ 155,876  $ 170,010  $ 605,155  $ 634,463

Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues 55.4  % 57.3  % 55.6  % 55.8  %

(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:

Three Months Ended

March 31, Year Ended

March 31,

2026 2025 2026 2025

(In thousands)

GAAP General and Administrative Expense 30,280    27,050  116,447    108,209

GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 10.8  % 9.1  % 10.7  % 9.5  %

Adjustments:

Costs associated with acquisitions (a)

2,756  —  3,228  —

Depreciation of idle assets recorded in G&A during remediation period (b)

135  —  135  —

Total adjustments 2,891  —  3,363  —

Non-GAAP Adjusted General and Administrative Expense $ 27,389  $ 27,050  $ 113,084  $ 108,209

Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues 9.7  % 9.1  % 10.4  % 9.5  %

(a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

(b) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

Three Months Ended March 31, Year Ended

March 31,

2026 2025 2026 2025

(In thousands)

GAAP Net Income $ 53,928    $ 50,128  $ 190,301    $ 214,605

Interest expense, net 11,428  10,759  42,339  47,632

Provision for income taxes 10,844  23,831  67,195  69,584

Depreciation and amortization 8,352  7,252  31,273  30,173

Non-GAAP EBITDA 84,552  91,970  331,108  361,994

Non-GAAP EBITDA Margin 30.0  % 31.0  % 30.4  % 31.8  %

Adjustments:

Amortization of inventory fair value step‑up 700  —  700  —

Acquired facility remediation, period overhead and idle capacity costs (a)

8,402  —  8,402  —

Costs associated with acquisitions in G&A (b)

2,756  —  3,228  —

Supplier loan write-off —  —  10,332  —

Tradename impairment —  12,466  —  12,466

Total adjustments 11,858  12,466  22,662  12,466

Non-GAAP Adjusted EBITDA $ 96,410  $ 104,436  $ 353,770  $ 374,460

Non-GAAP Adjusted EBITDA Margin 34.2  % 35.2  % 32.5  % 32.9  %

(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:

Three Months Ended March 31, Year Ended March 31,

2026 2026 Adjusted EPS 2025 2025 Adjusted EPS 2026 2026 Adjusted EPS 2025 2025 Adjusted EPS

(In thousands, except per share data)

GAAP Net Income and

Diluted EPS $ 53,928  $ 1.13  $ 50,128  $ 1.00  $ 190,301  $ 3.91  $ 214,605  $ 4.29

Adjustments:

Amortization of inventory fair value step‑up 700  0.01  —  —  700  0.01  —  —

Depreciation of idle manufacturing assets during remediation period (a) 610  0.01  —  —  610  0.01  —  —

Acquired facility remediation, period overhead and idle capacity costs (b) 8,402  0.18  —  —  8,402  0.17  —  —

Supplier loan write-off —  —  —  —  10,332  0.21  —  —

Costs associated with acquisition in General and administrative expense (c) 2,756  0.06  —  —  3,228  0.07  —  —

Tradename impairment —  —  12,466  0.25  —  —  12,466  0.25

Tax impact of adjustments (d)

(3,017) (0.06) (2,961) (0.06) (5,659) (0.12) (2,961) (0.06)

Normalized tax rate adjustment (e )

(4,831) (0.10) 6,266  0.13  5,430  0.11  2,236  0.04

Total adjustments 4,620  0.10  15,771  0.32  23,043  0.46  11,741  0.23

Non-GAAP Adjusted Net Income and Adjusted Diluted EPS $ 58,548  $ 1.23  $ 65,899  $ 1.32  $ 213,344  $ 4.38  $ 226,346  $ 4.52

(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.

(e) Income tax adjustment to adjust for discrete income tax items.

Note: Amounts may not add due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow:

Three Months Ended March 31, Year Ended

March 31,

2026 2025 2026 2025

(In thousands)

GAAP Net Income $ 53,928    $ 50,128  $ 190,301    $ 214,605

Adjustments:

Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 9,405  33,507  84,949  78,851

Changes in operating assets and liabilities as shown in the Statement of Cash Flows (20,492) (21,787) (17,623) (41,941)

Total adjustments (11,087) 11,720  67,326  36,910

GAAP Net cash provided by operating activities 42,841  61,848  257,627  251,515

Purchases of property and equipment (5,210) (3,479) (11,178) (8,224)

Non-GAAP Free Cash Flow $ 37,631  $ 58,369  $ 246,449  $ 243,291

Outlook for Fiscal Year 2027:

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow and Projected Non-GAAP Adjusted Free Cash Flow:

(In millions)

Projected FY'27 GAAP Net cash provided by operating activities $ 268

Additions to property and equipment for cash (26)

Projected FY'27 Non-GAAP Free Cash Flow 242

Costs associated with Pillar5 manufacturing optimization and integration 8

Projected FY'27 Non-GAAP Adjusted Free Cash Flow $ 250

Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Diluted Adjusted EPS:

Low High

Projected FY'27 GAAP Diluted EPS $ 4.31  $ 4.40

Costs associated with Pillar5 manufacturing optimization and integration 0.11 0.11

Projected FY'27 Non-GAAP Adjusted Diluted EPS $ 4.42  $ 4.51

EX-99.2

EX-99.2

Filename: exhibit992pbh_fy26xq4.htm · Sequence: 3

exhibit992pbh_fy26xq4

Full-Year Fiscal 2026 Results May 14th, 2026 Exhibit 99.2

F U L L - Y E A R F Y 2 6 R E S U L T S This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, and free cash flow; the impact of the Pillar5 acquisition, including on the supply of Clear Eyes®, sales of Clear Eyes® and category leadership in Eye Care; the Company’s ability to expand its Clear Eyes® supply, rebuild Eye Care retailer and safety stock, and reaccelerate Clear Eyes® distribution; the Company’s ability to execute on its brand-building strategy to drive free cash flow and maximize shareholder value; e-commerce and Gastrointestinal category growth; the Company’s capital allocation strategy and ability to delever; the impact of the Company’s announced acquisitions on its financial performance and the tax benefits from the acquisition of Breathe Right®; and the timing of closing of the Company’s announced acquisitions. Words such as “anticipate,” “continue,” “expect,” “enable,” “outlook,” “focus,” “plan,” “can,” “will,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability to and timing of any increase in the supply of Clear Eyes from Pillar5 and other suppliers; the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its other products and to avoid inflationary cost increases and supply disruption; the impact of economic and business conditions; consumer trends; competitive pressures; the impact of the Company’s advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; evolving U.S. and international tariffs, trade actions and regulatory activity; geopolitical instability; and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise. All non-GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule and in our May 13, 2026 earnings release in the “About Non-GAAP Financial Measures” section. Footnotes Reference footnotes on certain pages are detailed in the appendix on page 23. Safe Harbor Disclosure 2

F U L L - Y E A R F Y 2 6 R E S U L T S Agenda for Today’s Discussion 3 I. FY 26 and Performance Recap II. Drivers of Portfolio Growth III. Financial Overview IV.FY 27 Outlook & The Road Ahead

F U L L - Y E A R F Y 2 6 R E S U L T S I. FY 26 and Performance Recap

F U L L - Y E A R F Y 2 6 R E S U L T S FY 26 Performance Recap ◼ Revenue of $1.089 billion, down 4.3% versus prior year ◼ Eye care sales impacted by production volatility and capacity & quality upgrades ◼ International segment impacted by eye care supply and distributor order patterns ◼ Adjusted Gross Margin(2) of 55.6% approximately flat to prior year ◼ Adjusted Diluted EPS(2) of $4.38 versus $4.52 prior year ◼ Free Cash Flow(2) growth to $246.4 versus prior year ◼ $156 million in FY 26 share repurchases ◼ Ending leverage of 2.6x(3) ◼ Acquisitions of Breathe Right® and LaCorium Health on track for fiscal 2027 FY 26 Sales Highlights Disciplined Capital Allocation Superior Earnings and FCF 5

F U L L - Y E A R F Y 2 6 R E S U L T S History of Superior Performance 6 Proven Ability to Execute Value Creation Strategy Investing for Growth with Proven Brand-Building Playbook1 Superior Business Attributes Enable Free Cash Flow2 Scalable & Efficient Platform Supports Disciplined Capital Allocation3 +2.9% 5-Yr CAGR Revenue +6.2% 5-Yr CAGR Adj. EPS(2) +2.9% 5-Yr CAGR Adj. FCF(2)

F U L L - Y E A R F Y 2 6 R E S U L T S 7 Eye Care Outlook One Quarter Into Pillar5 Ownership Progress Made in 2026 FY 2027 Outlook Relentless Focus on Ensuring the Highest Quality Supply in Sterile Eye Care ◼ Eye Care supply ramp remains a strategic priority ◼ Meaningful progress on integration of Pillar5 after first full quarter of ownership ◼ Owned aseptic eye care facility proving to be strategically valuable ◼ Rigorous quality standards ensure consumer trust despite category headlines ◼ Identifying and partnering with supplemental suppliers to augment capacity ◼ Continued capex prioritization to enhance supply quality and resilience ◼ Anticipate sales improvement versus prior year as production ramps in FY27 ◼ Expect variable shipment patterns in FY27 given minimal safety stocks today ◼ Building capacity to produce the majority of volume in- house over time ◼ Strategic multi-year plan to return to category leadership in Eye Care

F U L L - Y E A R F Y 2 6 R E S U L T S II. Drivers of Portfolio Growth

F U L L - Y E A R F Y 2 6 R E S U L T S Proven Brand-Building Tactics Continue to Drive GI Growth Brand-Building Driving Consumption GrowthSustained Share GainsExpanding Category Reach in Multiple Ways ◼ Gaining market share (+2.1pts L12W)* driven by strong E-Commerce performance ◼ Successful innovation driving premiumization and sustained category expansion * MULO+C+Amazon Adult Rectal Laxatives for 12 week period ended 3/22/26 Private Label & Other (2%) #2 Brand (5%) ~57% Market Share* Best New Launch in Amazon Category +5% Market Share & YoY $ Sales Growth* Accelerate Penetration in Nausea Category Defend Motion Sickness Leadership with Engaging Content Expand Relevance Through GLP-1 Tailwinds Digital Activation Targeted HCP Programs 9

F U L L - Y E A R F Y 2 6 R E S U L T S Innovation Playbook Wide-Ranging to Address Consumer Needs 10 Extend Brand Through Better Consumer Experience or Claims Innovate Through Technology or Forms New Categories Expansion Product Development Initiatives Mental Alertness Skin Tags GLP-1 friendly GLP-1 friendly

F U L L - Y E A R F Y 2 6 R E S U L T S Continue to Drive Strong E-Commerce Growth 11 Continued strong performance across E-Commerce business *MULO+ Retail sales data and International assumptions as of 3/22/26 Optimizing Content to Changing Consumer Behavior with AI AdoptionE-Commerce as a % of Net Sales* ~4% ~11% ~14% ~16% ~18% FY 19 FY 21 FY 23 FY 25 FY 26 +4.5x New Product Development Seasonal Content Brand Refresh

F U L L - Y E A R F Y 2 6 R E S U L T S III. Financial Overview

F U L L - Y E A R F Y 2 6 R E S U L T S Fourth Quarter and FY 26 Performance FY 26 FY 25 Dollar values in millions, except per share data. $281.6 $96.4 $1.23 $296.5 $104.4 $1.32 Revenue Adjusted EBITDA Adjusted EPS (5.0%) (7.7%) (6.8%) 13 Q 4 $1,088.7 $353.8 $4.38 $1,137.8 $374.5 $4.52 Revenue Adjusted EBITDA Adjusted EPS (4.3%) (5.5%) (3.1%) (2) Revenue of $281.6 million, down 6.4% vs. prior year on an organic basis(1) Adjusted Diluted EPS(2) of $1.23, down 6.8% compared to $1.32 prior year Adjusted EBITDA(2) of $96.4 million compared to $104.4 million prior year F u ll -Y e a r (2) (2) (2)

F U L L - Y E A R F Y 2 6 R E S U L T S 3 Months Ended FY 26 Comments Detailed Financial Results for FY 26 ◼ Revenue down 4.5% organically(1) versus prior year – North America segment impacted by limited Clear Eyes supply and order timing in prior year – International segment down 3% excluding foreign currency due to limited eye care supply – Strong E-Commerce growth continued ◼ Adjusted Gross Margin(2) of 55.6% ◼ A&M of 13.7% of Revenue, consistent with expectations ◼ Adjusted G&A(2) of 10.4% of Revenue ◼ Adjusted Diluted EPS(2) down 3.1% vs. PY Dollar values in millions, except per share data Amounts may not add due to rounding 14 12 Months Ended Q4 FY 26 Q4 FY 25 % Chg FY 26 FY 25 % Chg Total Revenue 281.6$ 296.5$ (5.0%) 1,088.7$ 1,137.8$ (4.3%) Adj. Gross Profit (2) 155.9 170.0 (8.3%) 605.2 634.5 (4.6%) % Margin 55.4% 57.3% 55.6% 55.8% A&M 35.1 37.0 (5.2%) 148.8 155.7 (4.5%) % Total Revenue 12.5% 12.5% 13.7% 13.7% Adj. G&A (2) 27.4 27.1 1.3% 113.1 108.2 4.5% % Total Revenue 9.7% 9.1% 10.4% 9.5% D&A (ex. COGS) 5.4 5.1 7.4% 20.9 21.3 (1.6%) Adj. Operating Income (2) 88.0$ 100.9$ (12.8%) 322.3$ 349.2$ (7.7%) % Margin 31.2% 34.0% 29.6% 30.7% Adj. Earnings Per Share (2) 1.23$ 1.32$ (6.8%) 4.38$ 4.52$ (3.1%) Adj. EBITDA (2) 96.4$ 104.4$ (7.7%) 353.8$ 374.5$ (5.5%) % Margin 34.2% 35.2% 32.5% 32.9%

F U L L - Y E A R F Y 2 6 R E S U L T S Strong Free Cash Flow Continued in FY 26 Attractive Business Attributes Enable Robust Free Cash Flow Generation 15 Free Cash Flow(2) & Net Leverage(3) Enabling Efficient Allocation Dollar values in millions $222 $239 $243 $246 3.3x 2.8x 2.4x 2.6x FY 23 FY 24 FY 25 FY 26 Model with Low Capital Expenditures Leading Margin Profile Long-Term Cash Tax Savings Ongoing Focus on Profitability Key Attributes Repurchased $156 million (2.3 million shares) in FY 26 Investing in eye care manufacturing capabilities via acquisition of Pillar5 Low leverage providing flexibility to pursue strategic M&A

F U L L - Y E A R F Y 2 6 R E S U L T S Disciplined Capital Allocation Priorities 16 Invest in Current Brands to Drive Organic Growth 1 Focused on Debt Reduction to Enhance Optionality Prioritize Deleveraging Following Acquisition of Breathe Right® 2 Strategic Share Repurchases Opportunistic Share Repurchases Only if Warranted 3 Pursue M&A That is Attractive to Shareholders Continue to Assess, but Would Be Balanced Against Leverage 4 Strong Free Cash Flow Will Enabled Rapid Debt Reduction to Unlock Shareholder Value Anticipate approximately $900 million total Free Cash Flow(4) over the next three years enhancing shareholder value 16

F U L L - Y E A R F Y 2 6 R E S U L T S IV. FY 27 Outlook & The Road Ahead

F U L L - Y E A R F Y 2 6 R E S U L T S Portfolio & Strategy Well-Positioned for Continued Value Creation 18 Diversified Portfolio of Leading, Trusted Brands1 Established Organic Growth Playbook2 Superior Financial Profile Generating Consistent Cash Flow3 Scalable Platform4 Organic Growth Engine Reinforced by M&A5 Prestige’s Business Attributes & Execution Drive Superior Shareholder Value Creation

F U L L - Y E A R F Y 2 6 R E S U L T S Initial FY 27 Outlook ◼ Revenues of $1,100 to $1,121 million — Organic growth of approximately 1% to 3% ◼ Continue to emphasize brand-building across a diverse, needs-based portfolio ◼ Projecting improved shipment trends in eye care ◼ Pending acquisitions not yet included ◼ Adjusted Diluted EPS of $4.42 to $4.51(5), tracking sales growth ◼ Gross margin relatively consistent to prior year ◼ G&A reflects addition of Pillar5, normalized incentive comp ◼ Free Cash Flow(4) of $250 million or more ◼ Expect to close Breathe Right® and LaCorium Health in June and July, respectively ◼ Prioritizing debt reduction for the balance of fiscal 2027 Top Line Trends Free Cash Flow EPS 19

F U L L - Y E A R F Y 2 6 R E S U L T S M&A Strategy at Work: Portfolio-Enhancing Consumer Health Deals ✓ Iconic #1 brand synonymous with the nasal strip category and represents expansion into a new category for Prestige ✓ Diversified portfolio of trusted, established brands with loyal consumer followings ✓ Immediately accretive to Prestige’s gross and EBITDA margins ✓ Supports Prestige’s long-term organic growth targets ✓ $150 million estimated present value of future tax savings ~66% ~34% ~$200M Revenue Other Loyalty Brands #1 Category- Synonymous Brand with Global Reach ✓ Sustained double-digit top-line growth for over a decade ✓ Anticipate revenue accretion via category tailwinds and brand expansion ✓ Global platform across Australia & New Zealand (~75% of business), North America, Middle East, and Asia ✓ Asset-light model providing robust cash flow generation ✓ Leverage distribution network and other operating expertise for significant revenue and cost synergies ~70% ~20% ~10% ~$40M Revenue Leader in therapeutic lip, skin, and foot care 20 Breathe Right® & Other OTC Brands LaCorium Health

F U L L - Y E A R F Y 2 6 R E S U L T S Three-Year Roadmap Points to Outsized Value Creation Revenue Growth Financial Discipline Leading Free Cash Flow ✓ Proven strong & sustainable free cash flow model ✓ Leverage reduction focus unlocks future deployment optionality ✓ Enhanced by robust profitability and cash tax savings 21 Anticipate ~10% revenue growth CAGR Anticipate EPS CAGR of ~8% ✓ Accretive revenue growth from Breathe Right & LaCorium ✓ Fast-growing International OTC approaching ~20% of revenue ✓ Sterile eye supply from low base provides potential upside, supported by expanding long-term capacity ✓ Disciplined financial management to sustain earnings momentum ✓ Re-establishment of pre-payable debt adds magnifying effect Anticipate ~$900M total Free Cash Flow(2) over next three years Business Well Positioned to Exceed Long-term Algorithm Over Next Three Years

F U L L - Y E A R F Y 2 6 R E S U L T S Q&A

F U L L - Y E A R F Y 2 6 R E S U L T S Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated May 13, 2026 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Gross Profit, Adjusted Gross Margin, Adjusted G&A, Adjusted Operating Income, Adjusted Net Income, Adjusted Diluted EPS, EBITDA & EBITDA Margin, Free Cash Flow, and Net Debt are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated May 13, 2026 in the “About Non-GAAP Financial Measures” section. (3) Leverage ratio reflects net debt / covenant defined EBITDA. (4) Free Cash Flow for FY 27 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our earnings release dated May 13, 2026 in the “About Non-GAAP Financial Measures” section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures. (5) Adjusted EPS for FY 27 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in the attached Reconciliation Schedules and / or in our earnings release dated May 13, 2026 in the “About Non-GAAP Financial Measures” section and is calculated based on projected EPS adjusted for anticipated costs associated with Pillar5 manufacturing optimization and integration. 23

F U L L - Y E A R F Y 2 6 R E S U L T S 24 Reconciliation Schedules Adjusted Gross Margin Organic Revenue Change Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Total Revenues 281,617$ 296,518$ 1,088,705$ 1,137,762$ Revenue Change (5.0%) (4.3%) Adjustments: Impact of foreign currency exchange rates - 4,292 - 2,718 Total adjustments -$ 4,292$ -$ 2,718$ Non-GAAP Organic Revenues 281,617$ 300,810$ 1,088,705$ 1,140,480$ Non-GAAP Organic Revenue Change (6.4%) (4.5%) (a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. (b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Total Revenues 281,617$ 296,518$ 1,088,705$ 1,137,762$ GAAP Gross Profit 146,299$ 170,010$ 595,578$ 634,463$ GAAP Gross Profit as a Percentage of GAAP Total Revenue 51.9% 57.3% 54.7% 55.8% Adjustments: Amortization of inventory fair value step‑up 700 - 700 - Depreciation of idle manufacturing assets during remediation period (a) 475 - 475 - Acquired facility remediation, period overhead and idle capacity costs (b) 8,402 - 8,402 - Total adjustments 9,577 - 9,577 - Non-GAAP Adjusted Gross Margin 155,876$ 170,010$ 605,155$ 634,463$ Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues 55.4% 57.3% 55.6% 55.8%

F U L L - Y E A R F Y 2 6 R E S U L T S 25 Reconciliation Schedules (Continued) Adjusted G&A Expense (a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. (b) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP General and Administrative Expense 30,280$ 27,050$ 116,447$ 108,209$ GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 10.8% 9.1% 10.7% 9.5% Adjustments: Costs associated with acquisition (a) 2,756 - 3,228 - Depreciation of idle assets recorded in G&A during remediation period (b) 135 - 135 - Total adjustments 2,891 - 3,363 - Non-GAAP Adjusted General and Administrative Expense 27,389$ 27,050$ 113,084$ 108,209$ Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues 9.7% 9.1% 10.4% 9.5%

F U L L - Y E A R F Y 2 6 R E S U L T S 26 Reconciliation Schedules (Continued) Adjusted EBITDA and EBITDA Margin (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. (b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Net Income 53,928$ 50,128$ 190,301$ 214,605$ Interest expense, net 11,428 10,759 42,339 47,632 Provision for income taxes 10,844 23,831 67,195 69,584 Depreciation and amortization 8,352 7,252 31,273 30,173 Non-GAAP EBITDA 84,552 91,970 331,108 361,994 Non-GAAP EBITDA Margin 30.0% 31.0% 30.4% 31.8% Adjustments: Amortization of inventory fair value step‑up 700 - 700 - Acquired facility remediation, period overhead and idle capacity costs (a) 8,402 - 8,402 - Costs associated with acquisitions in G&A (b) 2,756 - 3,228 - Supplier loan write-off - - 10,332 - Tradename impairment - 12,466 - 12,466 Total adjustments 11,858 12,466 22,662 12,466 Non-GAAP Adjusted EBITDA 96,410$ 104,436$ 353,770$ 374,460$ Non-GAAP Adjusted EBITDA Margin 34.2% 35.2% 32.5% 32.9%

F U L L - Y E A R F Y 2 6 R E S U L T S 27 Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 2021 Net Income Adjusted EPS Net Income Adjusted EPS Net Income Adjusted EPS Net Income Adjusted EPS Net Income Adjusted EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS 53,928$ 1.13$ 50,128$ 1.00$ 190,301$ 3.91$ 214,605$ 4.29$ 164,682$ 3.25$ Adjustments: Amortization of inventory fair value step‑up 700 0.01 - - 700 0.01 - - - - Depreciation of idle manufacturing assets during remediation period (a) 610 0.01 - - 610 0.01 - - - - Acquired facility remediation, period overhead and idle capacity costs (b) 8,402 0.18 - - 8,402 0.17 - - - - Supplier loan write-off - - - - 10,332 0.21 - - - - Costs associated with acquisition in General and administrative expense (c) 2,756 0.06 - - 3,228 0.07 - - - - Loss on extinguishment of debt - - - - - - - - 12,327 0.24 Tradename impairment - - 12,466 0.25 - - 12,466 0.25 - - Tax impact of adjustments (d) (3,017) (0.06) (2,961) (0.06) (5,659) (0.12) (2,961) (0.06) (2,986) (0.06) Normalized tax rate adjustment (e) (4,831) (0.10) 6,266 0.13 5,430 0.11 2,236 0.04 (10,025) (0.20) Total Adjustments 4,620 0.10 15,771 0.32 23,043 0.46 11,741 0.23 (684) (0.01) Non-GAAP Adjusted Net Income and Adjusted EPS 58,548$ 1.23$ 65,899$ 1.32$ 213,344$ 4.38$ 226,346$ 4.52$ 163,998$ 3.24$ (a) Represents depreciation expense recorded during the remediation period following the acquisition of the Pillar5 facility, during which certain production lines were not operating. (b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of the Pillar5 facility, during which production was significantly constrained. (c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. (d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure. (e) Income tax adjustment to adjust for discrete income tax items.

F U L L - Y E A R F Y 2 6 R E S U L T S 28 Reconciliation Schedules (Continued) Adjusted Free Cash Flow Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Net Income 53,928$ 50,128$ 190,301$ 214,605$ Adjustments: Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 9,405 33,507 84,949 78,851 Changes in operating assets and liabilities as shown in the Statement of Cash Flows (20,492) (21,787) (17,623) (41,941) Total adjustments (11,087) 11,720 67,326 36,910 GAAP Net cash provided by operating activities 42,841 61,848 257,627 251,515 Purchases of property and equipment (5,210) (3,479) (11,178) (8,224) Non-GAAP Free Cash Flow 37,631$ 58,369$ 246,449$ 243,291$ 2021 2022 2023 2024 (In Thousands) GAAP Net Income (Loss) 164,682$ 205,381$ (82,306)$ 209,339$ Adjustments Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 76,523 65,487 365,877 79,418 Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows (5,598) (10,946) (53,855) (39,831) Total adjustments 70,925 54,541 312,022 39,587 GAAP Net cash provided by operating activities 235,607 259,922 229,716 248,926 Purchases of property and equipment (22,243) (9,642) (7,784) (9,550) Non-GAAP Free Cash Flow 213,364 250,280 221,932 239,376 Integration, transition and other payments associated with acquisitions/divestitures - 3,465 - - Total adjustments - 3,465 - - Non-GAAP Adjusted Free Cash Flow 213,364$ 253,745$ 221,932$ 239,376$

F U L L - Y E A R F Y 2 6 R E S U L T S 29 Reconciliation Schedules (Continued) Projected Free Cash Flow Projected Adjusted Earnings Per Share Low High Projected FY'27 GAAP Diluted EPS 4.31$ 4.40$ Costs associated with Pillar5 manufacturing optimization and integration 0.11$ 0.11$ Projected FY'27 Non-GAAP Adjusted Diluted EPS 4.42$ 4.51$ (in millions) Projected FY'26 GAAP Net cash provided by operating activities 268$ Additions to property and equipment for cash (26) Projected FY'26 Non-GAAP Free Cash Flow 242 Costs associated with Pillar5 manufacturing optimization and integration 8 Projected FY'26 Non-GAAP Adjusted Free Cash Flow 250$

F U L L - Y E A R F Y 2 6 R E S U L T S FY 27 Financial Outlook Metric Guidance Revenue ◼ $1.100 to $1.121 billion ◼ Organic growth of 1% to 3%(1) Gross Margin ◼ 55.0 to 56.0% Marketing ◼ Over 13% of net revenue General & Administrative ◼ ~10.5% of net revenue Interest Expense ◼ $43 million in interest expense Tax Rate ◼ ~24% effective tax rate EPS ◼ $4.42 to $4.51 Free Cash Flow(4) ◼ $250 million or more 30

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4001.jpg · Sequence: 7

Binary file (140497 bytes)

Download exhibit992pbh_fy26xq4001.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4002.jpg · Sequence: 8

Binary file (194737 bytes)

Download exhibit992pbh_fy26xq4002.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4003.jpg · Sequence: 9

Binary file (55289 bytes)

Download exhibit992pbh_fy26xq4003.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4004.jpg · Sequence: 10

Binary file (45093 bytes)

Download exhibit992pbh_fy26xq4004.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4005.jpg · Sequence: 11

Binary file (106564 bytes)

Download exhibit992pbh_fy26xq4005.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4006.jpg · Sequence: 12

Binary file (79493 bytes)

Download exhibit992pbh_fy26xq4006.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4007.jpg · Sequence: 13

Binary file (122836 bytes)

Download exhibit992pbh_fy26xq4007.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4008.jpg · Sequence: 14

Binary file (45881 bytes)

Download exhibit992pbh_fy26xq4008.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4009.jpg · Sequence: 15

Binary file (118659 bytes)

Download exhibit992pbh_fy26xq4009.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4010.jpg · Sequence: 16

Binary file (101188 bytes)

Download exhibit992pbh_fy26xq4010.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4011.jpg · Sequence: 17

Binary file (155525 bytes)

Download exhibit992pbh_fy26xq4011.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4012.jpg · Sequence: 18

Binary file (43475 bytes)

Download exhibit992pbh_fy26xq4012.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4013.jpg · Sequence: 19

Binary file (107213 bytes)

Download exhibit992pbh_fy26xq4013.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4014.jpg · Sequence: 20

Binary file (136661 bytes)

Download exhibit992pbh_fy26xq4014.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4015.jpg · Sequence: 21

Binary file (125521 bytes)

Download exhibit992pbh_fy26xq4015.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4016.jpg · Sequence: 22

Binary file (105955 bytes)

Download exhibit992pbh_fy26xq4016.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4017.jpg · Sequence: 23

Binary file (47273 bytes)

Download exhibit992pbh_fy26xq4017.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4018.jpg · Sequence: 24

Binary file (93278 bytes)

Download exhibit992pbh_fy26xq4018.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4019.jpg · Sequence: 25

Binary file (102583 bytes)

Download exhibit992pbh_fy26xq4019.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4020.jpg · Sequence: 26

Binary file (142917 bytes)

Download exhibit992pbh_fy26xq4020.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4021.jpg · Sequence: 27

Binary file (130258 bytes)

Download exhibit992pbh_fy26xq4021.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4022.jpg · Sequence: 28

Binary file (34999 bytes)

Download exhibit992pbh_fy26xq4022.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4023.jpg · Sequence: 29

Binary file (127121 bytes)

Download exhibit992pbh_fy26xq4023.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4024.jpg · Sequence: 30

Binary file (134523 bytes)

Download exhibit992pbh_fy26xq4024.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4025.jpg · Sequence: 31

Binary file (95597 bytes)

Download exhibit992pbh_fy26xq4025.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4026.jpg · Sequence: 32

Binary file (110930 bytes)

Download exhibit992pbh_fy26xq4026.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4027.jpg · Sequence: 33

Binary file (130207 bytes)

Download exhibit992pbh_fy26xq4027.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4028.jpg · Sequence: 34

Binary file (141231 bytes)

Download exhibit992pbh_fy26xq4028.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4029.jpg · Sequence: 35

Binary file (93938 bytes)

Download exhibit992pbh_fy26xq4029.jpg

GRAPHIC

GRAPHIC

Filename: exhibit992pbh_fy26xq4030.jpg · Sequence: 36

Binary file (70159 bytes)

Download exhibit992pbh_fy26xq4030.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 38

v3.26.1

Cover

May 13, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 13, 2026

Entity Registrant Name

PRESTIGE CONSUMER HEALTHCARE INC.

Entity Central Index Key

0001295947

Amendment Flag

false

Entity Incorporation, State or Country Code

DE

Entity File Number

001-32433

Entity Tax Identification Number

20-1297589

Entity Address, Address Line One

660 White Plains Road

Entity Address, City or Town

Tarrytown

Entity Address, State or Province

NY

Entity Address, Postal Zip Code

10591

City Area Code

914

Local Phone Number

524-6800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Title of 12(b) Security

Common stock, par value $0.01 per share

Trading Symbol

PBH

Security Exchange Name

NYSE

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration